Swiss pharmaceutical company Novartis has dismissed criticism that it allegedly withheld information about animal testing data inaccuracies to United States authorities for a human gene therapy.
This content was published on
1 minute
swissinfo.ch/ug
NovartisExternal link said its subsidiary in California began investigating the alleged data manipulation for its gene therapy Zolgensma as soon as it learned about it. Once the company had interim conclusions, it shared the informationExternal link with the US Food and Drug Administration (FDA).
The agency said Novartis did not disclose the information about suspected data manipulation until after the $2.1 million (CHF2.1) therapy treatment for children under the age of two won approval by the US regulator in May.
In a statement, the pharma company explained that the data in question were a small portion of its overall submission and limited to an older process no longer in use.
“The assays in question were used for initial product testing and are nor currently used for commercial product release,” Novartis said.
According to the company, Zolgensma, the most expensive treatment ever, is safe, of high quality and effective in treating patients with spinal muscular atrophy.
The FDA has indicated that the drug will remain on the market. The company’s actions are being assessed and could lead to criminal or civil penalties if appropriate.
More
More
How can a drug cost $2.1 million?
This content was published on
US authorities have approved a $2.1 million gene therapy, making it the most expensive drug ever. Can such a price tag be justified?
In Switzerland more people are being referred to electrical therapies or psychedelic-assisted psychotherapy. Are there similar approaches where you live?
This content was published on
A prisoner who escaped on Thursday in Baden, canton Aargau, is still on the run. The 23-year-old Albanian, who was in custody for burglary, was wearing handcuffs when he escaped.
Swiss city places information boards next to Nazi memorial
This content was published on
The city of Chur in eastern Switzerland has erected four information boards next to the Nazi memorial in the Daleu cemetery.
Swiss heat: parallels drawn with 2003 ‘summer of century’
This content was published on
Looking at the current weather situation in Switzerland, the private weather service MeteoNews has drawn parallels with the hot summer of 2003.
Syria: Switzerland calls for ceasefire to be respected in Suweida
This content was published on
Switzerland has condemned the attacks on civilians in the southern Syrian town of Suweida and has called on all parties to respect the ceasefire in the Druze stronghold.
Swiss reinforce ground-air defence with German systems
This content was published on
Switzerland has purchased five IRIS-T SLM systems for ground-based air defence from Germany, the Federal Office for Defence Procurement (armasuisse) said on Monday.
This content was published on
Individual deer are continuing to return to the Rosenberg cemetery in Winterthur, northeastern Switzerland, even after an eviction campaign last winter.
Hardly any interest earned on savings accounts in Switzerland
This content was published on
Interest rates on savings accounts in Switzerland have fallen significantly. The brief high in savings interest rates is over, according to a study by online comparison service Moneyland.
This content was published on
A group of around 25 men in uniforms of the Wehrmacht – the army of Nazi Germany – crossed the Wildhorn massif on Saturday and were questioned by Bern cantonal police.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Pharma company Sandoz named in US price-fixing lawsuit
This content was published on
The Germany-based subsidiary of Novartis is targeted in a 44-state class action suit for breaching rules on fair competition.
This content was published on
Swiss pharmaceutical Novartis must face a US government lawsuit accusing it of paying millions of dollars in kickbacks to doctors.
This content was published on
Pressure groups Public Eye and Médecins du Monde have filed their objection to the European patent office in Munich. They claim that Kymriah was not invented by Novartis because the research behind the drug was carried out by public institutions. The medicament, which is used to treat leukaemia and lymph gland cancer on patients who have…
Novartis faces questions about proxy voting independence
This content was published on
Proxy votes submitted by shareholders ended up at Novartis headquarters instead of the elected representative ahead of the annual general meeting.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.